Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6–35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres

• Published in: Vaccine 2019-03, Vol.37 (13), p.1876-1884
• Main Authors: Pepin, Stephanie, Dupuy, Martin, Borja-Tabora, Charissa Fay Corazon, Montellano, May, Bravo, Lulu, Santos, Jaime, de Castro, Jo-Anne, Rivera-Medina, Doris Maribel, Cutland, Clare, Ariza, Miguel, Diez-Domingo, Javier, Gonzalez, Celia Diaz, Martinón-Torres, Federico, Papadopoulou-Alataki, Efimia, Theodoriadou, Maria, Kazek-Duret, Marie Pierre, Gurunathan, Sanjay, De Bruijn, Iris
• Format: Article
• Language: English
• Subjects: Antigens; Children; Clinical trials; Effectiveness; Efficacy; Hemispheres; Immunization; Immunogenicity; Influenza; Laboratories; Licenses; Northern Hemisphere; Quadrivalent inactivated influenza vaccine; Randomization; Safety; Seasons; Southern Hemisphere; Vaccine efficacy; Vaccines; Virions
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2018.11.074

•A quadrivalent split-virion influenza vaccine has been available since 2016.•This study examined its efficacy and safety in children aged 6–35 months.•5806 participants were included in both hemispheres over 4 seasons.•Efficacy was 50.98% vs. any influenza and 68.40% vs. vaccine-similar strains.•The quadrivalent split-virion influenza vaccine appeared safe in this population. A quadrivalent split-virion inactivated influenza vaccine (VaxigripTetra™, Sanofi Pasteur; IIV4) containing two A strains (H1N1 and H3N2) and B strains from both lineages (Victoria and Yamagata) was approved in Europe in 2016 for individuals aged ≥ 3 years. This study examined the efficacy and safety of IIV4 in children aged 6–35 months. This was a phase III randomised controlled trial conducted in Latin America, Asia, Africa, and Europe during the Northern Hemisphere 2014/2015 and 2015/2016 and Southern Hemisphere 2014 and 2015 influenza seasons. Healthy children aged 6–35 months not previously vaccinated against influenza were randomised to receive two full doses 28 days apart of IIV4, placebo, the licensed trivalent split-virion inactivated vaccine (IIV3), an investigational IIV3 containing a B strain from the alternate lineage. The primary objective was to demonstrate efficacy against influenza illness caused by any strain or vaccine-similar strains. The study enrolled 5806 participants. Efficacy, assessed in 4980 participants completing the study according to protocol, was demonstrated for IIV4. Vaccine efficacy was 50.98% (97% CI, 37.36–61.86%) against influenza caused by any A or B type and 68.40% (97% CI, 47.07–81.92%) against influenza caused by vaccine-like strains. Safety profiles were similar for IIV4, placebo, and the IIV3s, although injection-site reactions were slightly more frequent for IIV4 than placebo. IIV4 was safe and effective for protecting children aged 6–35 months against influenza illness caused by vaccine-similar or any circulating strains. EudraCT no. 2013-001231-51.